Oncology Biomarker Diagnostics

Linking molecular status to breakthroughs in cancer treatment

Intellectual Property

MolecularMD seeks to in-license molecular diagnostics intellectual property associated with blood-based and solid tumor cancers, and is dedicated to sub-licensing its diagnostic rights and tests to make the technologies available broadly to the medical community.

The value of biomarker intellectual property lies in its access to patients and physicians, which requires significant commercialization efforts to develop and prove the diagnostic test in partnership with pharmaceutical companies developing targeted therapies. MolecularMD works with leading academic cancer institutions that drive the discovery of oncology biomarkers, the cornerstones of personalized medicine. MolecularMD takes license to these discoveries and develops and validates biomarker diagnostics in its CLIA-certified and CAP-accredited Clinical Reference Laboratory.

MolecularMD collaborates with drug developers to conduct clinical trials that demonstrate the clinical utility of the biomarkers alongside the efficacy of targeted therapeutics. The success of this endeavor allows for new FDA-approved targeted therapies, which are supported by MolecularMD’s commercialization of companion diagnostic tests.  In this way, MolecularMD provides the discovering academic institutes and the drug developers with the clinical trial support and IVD capabilities needed to deliver the biomarkers and targeted therapies to patients and physicians. MolecularMD also sub-licenses its diagnostic rights and tests to other commercial laboratories and diagnostic test developers to ensure the licensed technologies are available to the public.

Please This email address is being protected from spambots. You need JavaScript enabled to view it. for more information.


Technologies Available for Sub-Licensing

Detection of BRAF V600E mutant DNA 

Detection of DDR2 Gene Mutations in Squamous Cell Lung Cancer

Detection of Acquired EGFR Drug Resistance: EGFR gene T790M mutation Kinase Mutations

Detection of Activating Fibroblast Growth Factor Receptor 2 (FGFR2) Mutations in Endometrial Cancer

Oncology Thought Leaders Series:
Brian Druker, MD speaks on the value of
companion diagnostics in patient outcomes